menu toggle

December 10, 2024

Now available Eribulin Mesylate Injection

Eribulin Mesylate Injection is a microtubule inhibitor indicated for the treatment of patients with:

  • Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.
  • Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

Please see full prescribing information here.

We are NABP accredited